Skip to main content
. 2010 Sep 29;48(12):4417–4425. doi: 10.1128/JCM.02458-09

TABLE 1.

Original 2009 and 2010 CLSI and FDA criteria for interpretation of susceptibility testing of carbapenems and for detection of carbapenemase production among Enterobacteriaceaea

Agent MIC breakpoint (μg/ml)
Disk diffusion breakpoint (mm)
S MHTb I R S MHTb I R
IPM ≤1 2-4 8 ≥16 ≥16 NA 14-15 ≤13
MEM ≤1 2-4 8 ≥16 ≥22 16-21 14-15 ≤13
ERT ≤1 2 4 ≥8 ≥22 19-21 16-18 ≤15
DORc ≤0.5 NA NA NA ≥23 NA NA NA
a

See references 5 and 6. S, susceptible; I, intermediate; R, resistant; MHT, modified Hodge test; NA, not applicable.

b

MHT is required to detect carbapenemase production. If MHT is positive, report MICs with no interpretation and with the following comment. “This isolate demonstrates carbapenemase production. The clinical efficacy of the carbapenems has not been established for treating infections caused by Enterobacteriaceae that test carbapenem susceptible but demonstrate carbapenemase production in vitro.” If MHT is negative, report carbapenems as susceptible (5, 6).

c

Food and Drug Administration criteria are given for DOR.